Additional references
e1. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62(3):229-234.
doi:10.1002/ana.21164
e2. Farid K, Charidimou A, Baron J-C. Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: A systematic critical update.
NeuroImage Clin. 2017;15(May):247-263. doi:10.1016/j.nicl.2017.05.002 e3. Ezawa N, Katoh N, Oguchi K, Yoshinaga T, Yazaki M, Sekijima Y.
Visualization of multiple organ amyloid involvement in systemic amyloidosis using 11C-PiB PET imaging. Eur J Nucl Med Mol Imaging. 2018;45(3):452- 461. doi:10.1007/s00259-017-3814-1
e4. Maia LF, Maceski A, Conceição I, et al. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid.
2020;27(2):97-102. doi:10.1080/13506129.2019.1708716
e5. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H.
Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019:1-12. doi:10.1136/jnnp-2018-320106
e6. Llull L, Berenguer J, Yagüe J, Graus F. Amiloidosis leptomeníngea debida a la mutación A25T TTR. A propósito de un caso. Neurologia. 2014;29(6):382-384.
doi:10.1016/j.nrl.2012.12.006
e7. Mascalchi M, Salvi F, Pirini MG, et al. Transthyretin amyloidosis and superficial siderosis of the CNS. Neurology. 1999;53(7):1498-1498.
doi:10.1212/WNL.53.7.1498
e8. Hofer P-Å, Andersson R. Postmortem findings in primary familial amyloidosis
with polyneuropathy: A Study Based on Six Cases from Northern Sweden.
Acta Pathol Microbiol Scand Sect A Pathol. 1975;83 A(3):309-322.
doi:10.1111/j.1699-0463.1975.tb01878.x
e9. Attems J, Jellinger K, Thal DR, Van Nostrand W. Review: Sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol. 2011;37(1):75-93.
doi:10.1111/j.1365-2990.2010.01137.x
e10. Takahashi K, Yi S, Kimura Y, Araki S. Familial amyloidotic polyneuropathy type 1 in Kumamoto, Japan: A clinicopathologic, histochemical,
immunohistochemical, and ultrastructural study. Hum Pathol. 1991;22(6):519- 527. doi:10.1016/0046-8177(91)90227-G
e11. Hagiwara K, Ochi H, Suzuki S, et al. Highly selective leptomeningeal
amyloidosis with transthyretin variant Ala25Thr. Neurology. 2009;72(15):1358- 1360. doi:10.1212/WNL.0b013e3181a0fe74
e12. Shimizu Y, Takeuchi M, Matsumura M, Tokuda T, Iwata M. A case of biopsy- proven leptomeningeal amyloidosis and intravenous Ig-responsive
polyneuropathy associated with the Ala25Thr transthyretin gene mutation.
Amyloid. 2006;13(1):37-41. doi:10.1080/13506120600551814
e13. Koike H, Ikeda SIS, Takahashi M, et al. Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy. Neurology.
2016;87(21):2220-2229. doi:10.1212/WNL.0000000000003362 e14. Makover A, Moriwaki H, Ramakrishnan R, Saraiva MJM, Blaner WS,
Goodman DeWitt S. Plasma transthyretin. Tissue sites of degradation and turnover in the rat. J Biol Chem. 1988;263(18):8598-8603. doi:10.1016/S0021- 9258(18)68346-2
e15. Alemi M, Gaiteiro C, Ribeiro CA, et al. Transthyretin participates in beta-
amyloid transport from the brain to the liver- involvement of the low-density lipoprotein receptor-related protein 1? Sci Rep. 2016;6(October 2015):1-15.
doi:10.1038/srep20164
e16. Sweeney MD, Sagare AP, Zlokovic B V. Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol.
2018;14(3):133-150. doi:10.1038/nrneurol.2017.188
e17. Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to dementia. Science (80- ). 2020;370(6512):50-56.
doi:10.1126/science.abb8739
e18. Harkany T, Garzuly F, Csanaky G, et al. Cutaneous lymphatic amyloid
deposits in “Hungarian-type” familial transthyretin amyloidosis: A case report.
Br J Dermatol. 2002;146(4):674-679. doi:10.1046/j.1365-2133.2002.04594.x e19. Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic
factors of familial amyloid polyneuropathy after liver transplantation. Brain.
2000;123(7):1495-1504. doi:10.1093/brain/123.7.1495
e20. Schweitzer K, Ehmann D, García R, Alport E. Oculoleptomeningeal amyloidosis in 3 individuals with the transthyretin variant Tyr69His. Can J Ophthalmol. 2009;44(3):317-319. doi:10.3129/i09-023
e21. Urban PP, Hertkorn C, Schattenberg JM, et al. Leptomeningeal familial amyloidosis: A rare differential diagnosis of leptomeningeal enhancement in MRI. J Neurol. 2006;253(9):1238-1240. doi:10.1007/s00415-006-0169-0 e22. Barreiros A-P, Post F, Hoppe-Lotichius M, et al. Liver transplantation and
combined liver-heart transplantation in patients with familial amyloid
polyneuropathy: A single-center experience. Liver Transplant. 2010;16(3):314- 323. doi:10.1002/lt.21996
e23. Monteiro C, Martins da Silva A, Ferreira N, et al. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary
ATTRV30M (p.TTRV50M) amyloidosis patients. Amyloid. 2018;25(2):120-128.
doi:10.1080/13506129.2018.1479249
e24. Casal I, Monteiro S, Beirão JM. Tafamidis in hereditary ATTR amyloidosis–our experience on monitoring the ocular manifestations. Amyloid. 2016;23(4):262- 263. doi:10.1080/13506129.2016.1236332
e25. Salvi F, Volpe R, Pastorelli F, et al. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis. J Stroke Cerebrovasc Dis.
2018;27(9):e212-e214. doi:10.1016/j.jstrokecerebrovasdis.2018.04.033 e26. Sant’Anna R, Gallego P, Robinson LZ, et al. Repositioning tolcapone as a
potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun. 2016;7(May 2015). doi:10.1038/ncomms10787 e27. Gamez J, Salvadó M, Reig N, et al. Transthyretin stabilization activity of the
catechol- O -methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study.
Amyloid. 2019;26(2):74-84. doi:10.1080/13506129.2019.1597702
e28. Pinheiro F, Varej N, Esperante S, et al. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis. FEBS J.
2020. doi:10.1111/febs.15339
e29. Benson MD, Smith RA, Hung G, et al. Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment. Amyloid.
2010;17(2):43-49. doi:10.3109/13506129.2010.483121
e30. Gonçalves P, Martins H, Costelha S, Maia LF, Saraiva MJ. Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal
animal model. Amyloid. 2016;23(4):249-253.
doi:10.1080/13506129.2016.1256282
e31. Rydh A, Suhr O, Hietala SO, Åhlström KR, Pepys MB, Hawkins PN. Serum amyloid P component scintigraphy in familial amyloid polyneuropathy:
Regression of visceral amyloid following liver transplantation. Eur J Nucl Med.
1998;25(7):709-713. doi:10.1007/s002590050273
e32. Richards DB, Cookson LM, Berges AC, et al. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med.
2015;373(12):1106-1114. doi:10.1056/NEJMoa1504942
e33. Pepys MB. The pentraxins 1975-2018: Serendipity, diagnostics and drugs.
Front Immunol. 2018;9(OCT):1-18. doi:10.3389/fimmu.2018.02382
e34. Al-Shawi R, Tennent GA, Millar DJ, et al. Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo. Open Biol. 2016;6(2). doi:10.1098/rsob.150202 e35. No DEpletion of Serum amyloid P component In Alzheimer’s Disease:
DESPIAD. Double-blind placebo controlled randomised phase IIb trial of SAP depletion by CPHPC in mild Alzheimer’s disease. Univ Coll London. 2016.
https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003284-19/GB.
e36. Koike H, Nakamura T, Nishi R, et al. Widespread cardiac and vasomotor autonomic dysfunction in non-val30met hereditary transthyretin amyloidosis.
Intern Med. 2018;57(23):3365-3370. doi:10.2169/internalmedicine.1113-18 e37. Yamada Y, Fukushima T, Kodama S, et al. A case of cerebral amyloid
angiopathy-type hereditary ATTR amyloidosis with Y69H (p.Y89H) variant displaying transient focal neurological episodes as the main symptom.
Amyloid. 2019;26(4):251-252. doi:10.1080/13506129.2019.1632829
e38. Zeldenrust SR, Skinner M, Share J, Benson MD. A new transthyretin variant (his 69) associated with vitreous amyloid in an FAP family. Amyloid.
1994;1(1):17-22. doi:10.3109/13506129409148620
e39. Roe RH, Fisher Y, Eagle RC, Fine HF, Cunningham ET. Oculoleptomeningeal Amyloidosis in a Patient with a TTR Val30Gly Mutation in the Transthyretin Gene. Ophthalmology. 2007;114(11):33-37. doi:10.1016/j.ophtha.2007.07.007 e40. Martin SE, Benson MD, Hattab EM. The pathologic spectrum of
oculoleptomeningeal amyloidosis with Val30Gly transthyretin gene mutation in a postmortem case. Hum Pathol. 2014;45(5):1105-1108.
doi:10.1016/j.humpath.2013.10.037
